BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis
a study on Inflammatory Bowel Disease
Summary
- Eligibility
- for people ages 18-75 (full criteria)
- Location
- at San Diego, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Boehringer Ingelheim
- ID
- NCT03482635
- Phase
- Phase 2/3
- Study Type
- Interventional
- Last Updated